These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 24292520)

  • 1. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.
    Jaekel N; Behre G; Behning A; Wickenhauser C; Lange T; Niederwieser D; Al-Ali HK
    Bone Marrow Transplant; 2014 Feb; 49(2):179-84. PubMed ID: 24292520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.
    Chhabra S; Narra RK; Wu R; Szabo A; George G; Michaelis LC; D'Souza A; Dhakal B; Drobyski WR; Fenske TS; Jerkins JH; Pasquini MC; Rizzo RD; Saber W; Shah NN; Shaw BE; Hamadani M; Hari PN
    Biol Blood Marrow Transplant; 2020 May; 26(5):893-901. PubMed ID: 31982543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
    Ho PJ; Bajel A; Burbury K; Dunlop L; Durrant S; Forsyth C; Perkins AC; Ross DM
    Intern Med J; 2017 Mar; 47(3):262-268. PubMed ID: 28260257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis.
    Shahnaz Syed Abd Kadir S; Christopeit M; Wulf G; Wagner E; Bornhauser M; Schroeder T; Crysandt M; Mayer K; Jonas J; Stelljes M; Badbaran A; Ayuketang Ayuk F; Triviai I; Wolf D; Wolschke C; Kröger N
    Eur J Haematol; 2018 Sep; 101(3):305-317. PubMed ID: 29791053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
    Shanavas M; Popat U; Michaelis LC; Fauble V; McLornan D; Klisovic R; Mascarenhas J; Tamari R; Arcasoy MO; Davies J; Gergis U; Ukaegbu OC; Kamble RT; Storring JM; Majhail NS; Romee R; Verstovsek S; Pagliuca A; Vasu S; Ernst B; Atenafu EG; Hanif A; Champlin R; Hari P; Gupta V
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):432-40. PubMed ID: 26493563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation.
    Barabanshikova MV; Zubarovsky IN; Savrasov VM; Korolkov AJ; Baykov VV; Botina AV; Vlasova JJ; Moiseev IS; Darskaya EI; Morozova EV; Afanasyev BV
    Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):140-145. PubMed ID: 30978308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical management of myelofibrosis with ruxolitinib.
    Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
    Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
    Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation.
    Kröger N; Shahnaz Syed Abd Kadir S; Zabelina T; Badbaran A; Christopeit M; Ayuk F; Wolschke C
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2152-2156. PubMed ID: 29800615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.
    Gupta V; Hari P; Hoffman R
    Blood; 2012 Aug; 120(7):1367-79. PubMed ID: 22700718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.
    Ballinger TJ; Savani BN; Gupta V; Kroger N; Mohty M
    Eur J Haematol; 2015 Feb; 94(2):115-9. PubMed ID: 25256963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis].
    Fujishima M; Fujishima N; Kitadate A; Guo Y; Watanabe A; Ubukawa K; Nara M; Yoshioka T; Kameoka Y; Takahashi N
    Rinsho Ketsueki; 2017; 58(7):743-748. PubMed ID: 28781268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
    Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis.
    Morozova EV; Barabanshikova MV; Moiseev IS; Shakirova AI; Barhatov IM; Ushal IE; Rodionov GG; Moiseev SI; Surkova EA; Lapin SV; Vlasova JJ; Rudakova TA; Darskaya EI; Baykov VV; Alyanski AL; Bondarenko SN; Afanasyev BV
    Acta Haematol; 2021; 144(2):158-165. PubMed ID: 32325461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
    Verstovsek S
    Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT.
    Kröger N; Sbianchi G; Sirait T; Wolschke C; Beelen D; Passweg J; Robin M; Vrhovac R; Helbig G; Sockel K; Conneally E; Rubio MT; Beguin Y; Finke J; Bernasconi P; Morozova E; Clausen J; von dem Borne P; Schaap N; Schroyens W; Patriarca F; Di Renzo N; Yeğin ZA; Hayden P; McLornan D; Yakoub-Agha I
    Leukemia; 2021 Dec; 35(12):3551-3560. PubMed ID: 34023851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
    Vaddi K; Sarlis NJ; Gupta V
    Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis.
    Cyriac S; Prem S; Salas MQ; Chen S; Al-Shaibani Z; Lam W; Law A; Gupta V; Michelis FV; Kim DDH; Lipton J; Kumar R; Mattsson J; Viswabandya A
    Eur J Haematol; 2021 Nov; 107(5):517-528. PubMed ID: 34260760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study.
    Gupta V; Kosiorek HE; Mead A; Klisovic RB; Galvin JP; Berenzon D; Yacoub A; Viswabandya A; Mesa RA; Goldberg J; Price L; Salama ME; Weinberg RS; Rampal R; Farnoud N; Dueck AC; Mascarenhas JO; Hoffman R
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):256-264. PubMed ID: 30205231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis.
    Wang Z; Jin X; Zeng J; Xiong Z; Chen X
    Ann Hematol; 2024 Sep; 103(9):3293-3301. PubMed ID: 38494551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.